(B1371012) AN OPEN-LABEL PHASE 1B STUDY OF PF-04449913
(GLASDEGIB) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH
PREVIOUSLY UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROME,
ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
This multi center open label Phase 1b study is designed to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined with azacitidine in patients with previously untreated Higher Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). This clinical study includes two components: (a) a safety lead in cohort (LIC) and (b) an expansion phase with an AML cohort and an MDS cohort.